Findings from Sojo University Yields New Data on Pulmonary Fibrosis (Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis)
By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Lung Diseases and Conditions are presented in a new report. According to news reporting originating in Kumamoto, Japan, by NewsRx journalists, research stated, "Carbon monoxide (CO) has potent anti-inflammatory and anti-oxidant effects. We report herein on the preparation of a nanotechnology-based CO donor, CO-bound hemoglobin-vesicles (CO-HbV)."
The news reporters obtained a quote from the research from Sojo University, "We hypothesized that CO-HbV could have a therapeutic effect on idiopathic pulmonary fibrosis (IPF), an incurable lung fibrosis, that is thought to involve inflammation and the production of reactive oxygen species (ROS). Pulmonary fibril formation and respiratory function were quantitatively evaluated by measuring hydroxyproline levels and forced vital capacity, respectively, using a bleomycin-induced pulmonary fibrosis mice model. CO-HbV suppressed the progression of pulmonary fibril formation and improved respiratory function compared to saline and HbV. The suppressive effect of CO-HbV on pulmonary fibrosis can be attributed to a decrease in ROS generation by inflammatory cells, NADPH oxidase 4 and the production of inflammatory cells, cytokines and transforming growth factor-beta in the lung. This is the first demonstration of the inhibitory effect of CO-HbV on the progression of pulmonary fibrosis via the anti-oxidative and anti-inflammatory effects of CO in the bleomycin-induced pulmonary fibrosis mice model."
According to the news reporters, the research concluded: "CO-HbV has the potential for use in the treatment of, not only IPF, but also a variety of other ROS and inflammation-related disorders."
For more information on this research see: Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. Biomaterials, 2014;35(24):6553-6562. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting S. Nagao, Sojo Univ, DDS Res Inst, Kumamoto 8600082, Japan. Additional authors for this research include K. Taguchi, H. Sakai, R. Tanaka, H. Horinouchi, H. Watanabe, K. Kobayashi, M. Otagiri and T. Maruyama (see also Lung Diseases and Conditions).
Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Japan, Drugs, Therapy, Kumamoto, Bleomycin, Chemicals, Chemistry, Hemoglobins, Inflammation, Glycopeptides, Blood Proteins, Carbon Monoxide, Pulmonary Fibrosis, Inorganic Carbon Compounds, Respiratory Tract Diseases, Lung Diseases and Conditions
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC